Do analysts recommend SCYX or RFAI?

SCYNEXIS presently has a consensus price target of $33.00, indicating a potential upside of 517.98%. Given SCYNEXIS's stronger consensus rating and higher probable upside, equities research analysts clearly believe SCYNEXIS is more favorable than RF Acquisition Corp II. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 RF Acquisition Corp II 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, SCYX or RFAI?

RF Acquisition Corp II has lower revenue, but higher earnings than SCYNEXIS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SCYNEXIS $20.60M 2.58 -$8.61M -$2.09 N/A RF Acquisition Corp II N/A N/A N/A N/A N/A

Does the media favor LFCR or SCYX?

In the previous week, Lifecore Biomedical had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 4 mentions for Lifecore Biomedical and 3 mentions for SCYNEXIS. Lifecore Biomedical's average media sentiment score of 0.73 beat SCYNEXIS's score of 0.25 indicating that Lifecore Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SCYNEXIS 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SCYX or MENS?

SCYNEXIS currently has a consensus target price of $33.00, indicating a potential upside of 517.98%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts plainly believe SCYNEXIS is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, SCYX or MENS?

Jyong Biotech has lower revenue, but higher earnings than SCYNEXIS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SCYNEXIS $20.60M 2.58 -$8.61M -$2.09 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Does the media prefer SCYX or MENS?

In the previous week, SCYNEXIS had 2 more articles in the media than Jyong Biotech. MarketBeat recorded 3 mentions for SCYNEXIS and 1 mentions for Jyong Biotech. SCYNEXIS's average media sentiment score of 0.25 beat Jyong Biotech's score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SCYNEXIS 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jyong Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SCYX or NRXP?

In the previous week, SCYNEXIS and SCYNEXIS both had 3 articles in the media. SCYNEXIS's average media sentiment score of 0.25 beat NRx Pharmaceuticals' score of -0.53 indicating that SCYNEXIS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SCYNEXIS 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NRx Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Does the media prefer AARD or SCYX?

In the previous week, Aardvark Therapeutics had 21 more articles in the media than SCYNEXIS. MarketBeat recorded 24 mentions for Aardvark Therapeutics and 3 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 0.25 beat Aardvark Therapeutics' score of 0.03 indicating that SCYNEXIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 23 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SCYNEXIS 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

SCYNEXIS (SCYX) Competitors

$5.34 +0.12 (+2.30%)

As of 09/3/2026 04:00 PM Eastern

Compare

SCYX vs. RFAI, LFCR, MENS, NRXP, and AARD

Should you buy SCYNEXIS stock or one of its competitors? SCYNEXIS's main competitors and comparable companies include RF Acquisition Corp II (RFAI), Lifecore Biomedical (LFCR), Jyong Biotech (MENS), NRx Pharmaceuticals (NRXP), and Aardvark Therapeutics (AARD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does SCYNEXIS compare to RF Acquisition Corp II?

SCYNEXIS (NASDAQ:SCYX) and RF Acquisition Corp II (NASDAQ:RFAI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

RF Acquisition Corp II has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. RF Acquisition Corp II's return on equity of 0.00% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-44.15%	-32.61%
RF Acquisition Corp II	N/A	N/A	N/A

54.4% of SCYNEXIS shares are held by institutional investors. 4.1% of SCYNEXIS shares are held by company insiders. Comparatively, 39.1% of RF Acquisition Corp II shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

RF Acquisition Corp II has lower revenue, but higher earnings than SCYNEXIS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	2.58	-$8.61M	-$2.09	N/A
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A

In the previous week, SCYNEXIS had 3 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 3 mentions for SCYNEXIS and 0 mentions for RF Acquisition Corp II. SCYNEXIS's average media sentiment score of 0.25 beat RF Acquisition Corp II's score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Overall Sentiment
SCYNEXIS	Neutral
RF Acquisition Corp II	Neutral

SCYNEXIS presently has a consensus price target of $33.00, indicating a potential upside of 517.98%. Given SCYNEXIS's stronger consensus rating and higher probable upside, equities research analysts clearly believe SCYNEXIS is more favorable than RF Acquisition Corp II.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
RF Acquisition Corp II	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SCYNEXIS has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, RF Acquisition Corp II has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

Summary

SCYNEXIS beats RF Acquisition Corp II on 7 of the 12 factors compared between the two stocks.

How does SCYNEXIS compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Lifecore Biomedical presently has a consensus target price of $6.50, indicating a potential upside of 49.43%. SCYNEXIS has a consensus target price of $33.00, indicating a potential upside of 517.98%. Given SCYNEXIS's stronger consensus rating and higher possible upside, analysts clearly believe SCYNEXIS is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Lifecore Biomedical had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 4 mentions for Lifecore Biomedical and 3 mentions for SCYNEXIS. Lifecore Biomedical's average media sentiment score of 0.73 beat SCYNEXIS's score of 0.25 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by insiders. Comparatively, 4.1% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

SCYNEXIS has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.28	-$40.50M	-$1.07	N/A
SCYNEXIS	$20.60M	2.58	-$8.61M	-$2.09	N/A

Lifecore Biomedical has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

Lifecore Biomedical has a net margin of -29.93% compared to SCYNEXIS's net margin of -41.79%. Lifecore Biomedical's return on equity of 0.00% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
SCYNEXIS	-41.79%	-44.15%	-32.61%

Summary

Lifecore Biomedical beats SCYNEXIS on 9 of the 16 factors compared between the two stocks.

How does SCYNEXIS compare to Jyong Biotech?

SCYNEXIS (NASDAQ:SCYX) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Jyong Biotech has lower revenue, but higher earnings than SCYNEXIS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	2.58	-$8.61M	-$2.09	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

Jyong Biotech has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. Jyong Biotech's return on equity of 0.00% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-44.15%	-32.61%
Jyong Biotech	N/A	N/A	N/A

SCYNEXIS has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.24, meaning that its share price is 124% more volatile than the broader market.

54.4% of SCYNEXIS shares are held by institutional investors. 4.1% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, SCYNEXIS had 2 more articles in the media than Jyong Biotech. MarketBeat recorded 3 mentions for SCYNEXIS and 1 mentions for Jyong Biotech. SCYNEXIS's average media sentiment score of 0.25 beat Jyong Biotech's score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jyong Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SCYNEXIS currently has a consensus target price of $33.00, indicating a potential upside of 517.98%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts plainly believe SCYNEXIS is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

SCYNEXIS beats Jyong Biotech on 8 of the 13 factors compared between the two stocks.

How does SCYNEXIS compare to NRx Pharmaceuticals?

SCYNEXIS (NASDAQ:SCYX) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 4.1% of SCYNEXIS shares are held by company insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

SCYNEXIS has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market.

In the previous week, SCYNEXIS and SCYNEXIS both had 3 articles in the media. SCYNEXIS's average media sentiment score of 0.25 beat NRx Pharmaceuticals' score of -0.53 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NRx Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

SCYNEXIS has a net margin of -41.79% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-44.15%	-32.61%
NRx Pharmaceuticals	-691.81%	N/A	-63.92%

SCYNEXIS has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	2.58	-$8.61M	-$2.09	N/A
NRx Pharmaceuticals	$1.23M	120.75	-$28.62M	-$0.55	N/A

SCYNEXIS currently has a consensus price target of $33.00, suggesting a potential upside of 517.98%. NRx Pharmaceuticals has a consensus price target of $34.50, suggesting a potential upside of 905.83%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe NRx Pharmaceuticals is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

NRx Pharmaceuticals beats SCYNEXIS on 8 of the 15 factors compared between the two stocks.

How does SCYNEXIS compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

In the previous week, Aardvark Therapeutics had 21 more articles in the media than SCYNEXIS. MarketBeat recorded 24 mentions for Aardvark Therapeutics and 3 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 0.25 beat Aardvark Therapeutics' score of 0.03 indicating that SCYNEXIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	23 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

54.4% of SCYNEXIS shares are held by institutional investors. 17.8% of Aardvark Therapeutics shares are held by insiders. Comparatively, 4.1% of SCYNEXIS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aardvark Therapeutics has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -44.15% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
SCYNEXIS	-41.79%	-44.15%	-32.61%

Aardvark Therapeutics has a beta of 3.74, suggesting that its stock price is 274% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Aardvark Therapeutics presently has a consensus price target of $15.33, indicating a potential upside of 167.60%. SCYNEXIS has a consensus price target of $33.00, indicating a potential upside of 517.98%. Given SCYNEXIS's higher probable upside, analysts plainly believe SCYNEXIS is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

SCYNEXIS has higher revenue and earnings than Aardvark Therapeutics. SCYNEXIS is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
SCYNEXIS	$20.60M	2.58	-$8.61M	-$2.09	N/A

Summary

Aardvark Therapeutics and SCYNEXIS tied by winning 8 of the 16 factors compared between the two stocks.

Get SCYNEXIS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCYX vs. The Competition

Export

Metric	SCYNEXIS	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$51.94M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-2.56	787.27	273.29	25.38
Price / Sales	2.58	753.78	613.45	97.56
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	0.79	12.33	12.89	6.14
Net Income	-$8.61M	$2.82B	$3.47B	$349.01M
7 Day Performance	-0.93%	2.59%	0.60%	-0.27%
1 Month Performance	-1.11%	6.95%	5.73%	0.68%
1 Year Performance	-23.18%	9.45%	25.35%	14.84%

SCYNEXIS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCYX SCYNEXIS	3.3087 of 5 stars	$5.34 +2.3%	$33.00 +518.0%	-20.5%	$51.94M	$20.60M	N/A	60	Gap Down
RFAI RF Acquisition Corp II	0.5948 of 5 stars	$51.09 +0.1%	N/A	+293.8%	$179.33M	N/A	N/A	N/A
LFCR Lifecore Biomedical	2.2612 of 5 stars	$4.64 +2.0%	$6.50 +40.1%	-43.6%	$175.64M	$128.87M	N/A	690
MENS Jyong Biotech	N/A	$2.23 +0.5%	N/A	-96.0%	$169.55M	N/A	N/A	31	News Coverage
NRXP NRx Pharmaceuticals	1.9434 of 5 stars	$3.67 +6.4%	$34.50 +840.1%	+31.9%	$158.91M	$1.23M	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCYX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SCYNEXIS (SCYX) Competitors

SCYX vs. RFAI, LFCR, MENS, NRXP, and AARD

How does SCYNEXIS compare to RF Acquisition Corp II?

Summary

How does SCYNEXIS compare to Lifecore Biomedical?

Summary

How does SCYNEXIS compare to Jyong Biotech?

Summary

How does SCYNEXIS compare to NRx Pharmaceuticals?

Summary

How does SCYNEXIS compare to Aardvark Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCYX vs. The Competition

SCYNEXIS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SCYNEXIS (SCYX) Competitors

SCYX vs. RFAI, LFCR, MENS, NRXP, and AARD

How does SCYNEXIS compare to RF Acquisition Corp II?

Is SCYX or RFAI more profitable?

Do insiders and institutionals have more ownership in SCYX or RFAI?

Which has stronger valuation & earnings, SCYX or RFAI?

Does the media refer more to SCYX or RFAI?

Do analysts recommend SCYX or RFAI?

Which has more volatility and risk, SCYX or RFAI?

Summary

How does SCYNEXIS compare to Lifecore Biomedical?

Do analysts recommend LFCR or SCYX?

Does the media favor LFCR or SCYX?

Do insiders & institutionals believe in LFCR or SCYX?

Which has preferable earnings and valuation, LFCR or SCYX?

Which has more volatility & risk, LFCR or SCYX?

Is LFCR or SCYX more profitable?

Summary

How does SCYNEXIS compare to Jyong Biotech?

Which has preferable valuation & earnings, SCYX or MENS?

Is SCYX or MENS more profitable?

Which has more volatility and risk, SCYX or MENS?

Do institutionals & insiders have more ownership in SCYX or MENS?

Does the media prefer SCYX or MENS?

Do analysts prefer SCYX or MENS?

Summary

How does SCYNEXIS compare to NRx Pharmaceuticals?

Do insiders and institutionals have more ownership in SCYX or NRXP?

Which has more risk & volatility, SCYX or NRXP?

Does the media refer more to SCYX or NRXP?

Is SCYX or NRXP more profitable?

Which has higher valuation & earnings, SCYX or NRXP?

Do analysts recommend SCYX or NRXP?

Summary

How does SCYNEXIS compare to Aardvark Therapeutics?

Does the media prefer AARD or SCYX?

Do insiders and institutionals believe in AARD or SCYX?

Is AARD or SCYX more profitable?

Which has more volatility & risk, AARD or SCYX?

Do analysts rate AARD or SCYX?

Which has better earnings & valuation, AARD or SCYX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCYX vs. The Competition

SCYNEXIS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools